BIOMARKER:

ALK fusion

Entrez ID:

Related biomarkers:

‹

›

ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Sensitive: A2 - Guideline
ALK fusion ALK fusion	Melanoma Melanoma	crizotinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Melanoma Melanoma	entrectinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: B - Late Trials
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	anlotinib Sensitive: C3 – Early Trials
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: C3 – Early Trials
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: C3 – Early Trials
ALK fusion ALK fusion	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	ceritinib Sensitive: C3 – Early Trials
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	pemetrexed Resistant: C3 – Early Trials
ALK fusion ALK fusion	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C4 – Case Studies
ALK fusion ALK fusion	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	gilteritinib Sensitive: D – Preclinical